ROR

RAR-related orphan receptor

Retinoic acid receptor-related orphan receptors (RORs) are a subfamily of the thyroid hormone receptor, which is a subfamily of the nuclear receptors and belonging to the orphan nuclear receptor family. The ROR subfamily contains three members: RORα (NR1F1), RORβ (NR1F2), and RORγ (NR1F3) and function as ligand-dependent transcription factors.

RORs are reported to activate transcription through ligand-dependent interactions with co-regulators and are involved in the development of secondary lymphoid tissues, autoimmune diseases, inflammatory diseases, the circadian rhythm, and metabolism homeostasis.

RORα and RORγ are important regulators of the immune system. The development and differentiation of Th17cells are dependent on these factors. RORγ is expressed in lymphoid tissue inducer cells, innate lymphoid cells, invariant natural killer T cells, and γδ T cells, which contribute to inflammation and autoimmune disease.

(±)-ML 209

Cat. No.: HY-126037

(±)-ML 209 (compound 4n), a diphenylpropanamide, is a retinoic acid-related orphan receptor **RORγ** antagonist with an IC_{50} of 1.1 μM. (±)-ML 209 inhibits RORγt transcriptional activity with an IC_{50} of 300 nM in HEK293t cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

3-Oxo-5β-cholanoic acid

(Dehydrolithocholic acid; 3-oxoLCA)

Cat. No.: HY-125801

3-Oxo-5β-cholanoic acid (Dehydrolithocholic acid), a bile acid metabolite, inhibits the diferentiation of **TH17** cells by directly binding to the key transcription factor **RORγt** (K_d=1.13 μM).



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

A-9758

Cat. No.: HY-126252

A-9758 is a RORγ ligand and a potent, selective **RORγt** inverse agonist (IC_{50}=5 nM), and exhibits robust potency against **IL-17A** release. A-9758 is effective in suppressing both Th17 differentiation and Th17 effector function.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ARN-6039

Cat. No.: HY-115777

ARN-6039 is an orally available inverse agonist of **RORγ** for autoimmune demyelinating disease.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

AZD-0284

Cat. No.: HY-120384

AZD-0284 is a selective inverse agonist of the nuclear receptor **RORγ**. AZD-0284 has the potential for plaque psoriasis vulgaris and respiratory tract disorders treatment.



Purity: 99.90%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Bevurogant

Cat. No.: HY-132810

Bevurogant is a retinoid-related **orphan receptor-gamma t (RORγt)** antagonist. Bevurogant can be used for the research of chronic inflammatory diseases.



Purity: 98.57%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BMS-986251

Cat. No.: HY-136527

BMS-986251 is an orally active and selective **RORγt** inverse agonist with an EC_{50} of 12 nM for RORγt GAL4. BMS-986251 inhibits **IL-17** with an EC_{50} of 24 nM in human whole blood assay.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cedirogant

(ABBV-157)

Cat. No.: HY-137434

Cedirogant (ABBV-157) is an orally active RORγt inverse agonist. Cedirogant can be used for psoriasis research.



Purity: 99.41%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Cintirorgon

(LYC-55716)

Cat. No.: HY-104037

Cintirorgon (LYC-55716) is a first-in-class, selective and orally bioavailable **RORγ** agonist.



Purity: 99.95%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

FM26

Cat. No.: HY-133128

FM26 (compound 25) is a potent and allosteric **retinoic acid receptor-related orphan receptor γt (RORγt)** inverse agonists with an IC_{50} of 264 nM. FM26 has a distinct isoxazole chemotype and effectively reduces IL-17a mRNA production in EL4 cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

GNE-0946

Cat. No.: HY-19774

GNE-0946 is a potent and selective **RORγ(RORc)** agonist with an EC_{50} value of 4 nM for HEK-293 cell.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GNE-6468

Cat. No.: HY-19775

GNE-6468 is a highly potent and selective **RORγ (RORc)** inverse agonist with an EC_{50} value of 13 nM for HEK-293 cell. GNE-6468 exhibits an EC_{50} of 30 nM for IL-17 PBMC.



Purity: 99.50%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 250 mg

GSK2981278

Cat. No.: HY-19770

GSK2981278 is a potent and selective **RORγ** inverse agonist. GSK2981278 inhibits activation of the il17 promoter and interferes RORγ-DNA binding.



Purity: 99.69%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

GSK805

Cat. No.: HY-12776

GSK805 is a potent, orally bioavailable, and CNS penetrant **RORγt** inhibitor with pIC_{50} of 8.4 and >8.2 for RORγ FRET assay and Th17 assay.



Purity: 98.26%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Methyl-3β-hydroxycholenate

Cat. No.: HY-100084

Methyl-3β-hydroxycholenate is a **ROR gamma** modulator extracted from patent US20110263046 A1, in figure 2.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Neoruscogenin

Cat. No.: HY-N2253

Neoruscogenin, a member of the steroidal sapogenin family, is a bioavailable, potent, and high-affinity agonist of the nuclear receptor **RORα (NR1F1)**.



Purity: 98.15%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Nobiletin

Cat. No.: HY-N0155

Nobiletin is a poly-methoxylated flavone from the citrus peel that improves memory loss. Nobiletin is a **retinoid acid receptor-related orphan receptors (RORs)** agonist.



Purity: 99.52%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PF-06747711

Cat. No.: HY-112706

PF-06747711 is a potent, selective, and orally active retinoic acid receptor-related orphan C2 (**RORC2**, also known as **RORγt**) inverse agonist, with an IC_{50} of 4.1 nM. Anti-skin inflammatory activity.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Retezorogant

Cat. No.: HY-145590

Retezorogant is a **retinoid-related orphan receptor γ (RORγ)** antagonist, extracted from patent WO2016093342 A1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ROR agonist-1

Cat. No.: HY-128353

ROR agonist-1 is a potent and orally bioavailable inverse agonist of the **retinoic acid receptor-related orphan receptor C2 (RORC2)**, inhibition of IL-17A production from human primary T_H 17 cells with a pIC_{50} of 7.5.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RORγ agonist 1

Cat. No.: HY-132900

RORγ agonist 1 is a potent and orally bioavailable **RORγ** agonist (EC_{50} = 21 nM) with antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RORγt agonist 1

Cat. No.: HY-126321

RORγt agonist 1 (compound 14) is a potent, orally bioavailable **RORγt** agonist with an EC_{50} of 20.8 nM. RORγt agonist 1 showes high metabolic stability, improved aqueous solubility and excellent mouse PK profile.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RORγt agonist 2

Cat. No.: HY-142937

RORγt agonist 2 is a potent agonist of **RORγt**. RORγt agonist 2 promotes the differentiation of Th17 cells and enhances the levels of pro-inflammatory cytokines, thereby increasing the cytotoxicity of lymphocytes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RORγt agonist 3

Cat. No.: HY-142938

RORγt agonist 3 is a potent agonist of **RORγt**. RORγt agonist 3 promotes the differentiation of Th17 cells and enhances the levels of pro-inflammatory cytokines, thereby increasing the cytotoxicity of lymphocytes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RORγt inhibitor 1

Cat. No.: HY-142296

RORγt inhibitor 1 is a **RORγt** allosteric inhibitor with an IC_{50} value of 1 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RORγt Inverse agonist 10

Cat. No.: HY-133552

RORγt Inverse agonist 10 is a potent and orally bioavailable **RORγt (retinoic acid receptor-related orphan nuclear receptor gamma t)** inverse agonist, with an IC_{50} of 51 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RORγt inverse agonist 13

Cat. No.: HY-131338

RORγt inverse agonist 13 (Compound 3i) is a potent, orally active and selective **RORγt** inverse agonist, with improved drug-like properties, with an IC_{50} of 63.8 nM.



Purity: 99.22%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RORγt inverse agonist 14

Cat. No.: HY-132195

RORγt inverse agonist 14 (8e) is a potent, orally active and selective **RORγt** inverse agonist (EC_{50} of 2.5 nM) with anti-inflammatory activity. RORγt inverse agonist 14 is used in the study for rheumatoid arthritis and psoriasis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RORγt Inverse agonist 2

Cat. No.: HY-111748

RORγt Inverse agonist 2 is a selective, orally active **RORγt** inverse agonist with an EC_{50} of 119 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RORγt inverse agonist 23

Cat. No.: HY-139847

RORγt inverse agonist 23 is a potent, selective, and orally available novel **retinoic acid receptor-related orphan receptor γt** inverse agonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RORγt inverse agonist 26

Cat. No.: HY-142806

RORγt inverse agonist 26 is a potent reverse agonist of **RORγt**. RORγt inverse agonist 26 regulates the differentiation of Th17 cells and inhibits the production of IL-17.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RORγt inverse agonist 28

Cat. No.: HY-142703

RORγt inverse agonist 28 is a potent reverse agonist of **RORγt**. RORγt inverse agonist 28 regulates the differentiation of Th17 cells and inhibits the production of IL-17.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RORγt Inverse agonist 3

Cat. No.: HY-128573

RORγt Inverse agonist 3 is a potent, selective and orally active **RORγ** inverse agonist, with **EC_{50}**s of 0.22 μM and 0.15 μM for hRORγ and RORγt (human IL-17 cells), respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RORγt Inverse agonist 6

Cat. No.: HY-130243

RORγt Inverse agonist 6 (compound 43) is a **RORγt** inverse agonist for the study of Th17-driven autoimmune diseases. RORγt Inverse agonist 6 (compound 43) suppresses IL-17A gene expression by IL-23 stimulation in vivo.



Purity: 98.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RORγt Inverse agonist 8

Cat. No.: HY-122737

RORγt Inverse agonist 8 is a potent, selective, orally bioavailable **RORγt** inverse agonist, with an **IC_{50}** of 19 nM for human RORγt-LBD.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RORγt modulator 4

Cat. No.: HY-142939

RORγt modulator 4 is a **RORγt** modulator. RORγt modulator 4 has an activity to modulate IL-17A production in cells derived from mouse spleen (WO2018030550A1; compound 146).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RORγt modulator 5

Cat. No.: HY-142940

RORγt modulator 5 is a **RORγt** modulator with a **K_i** value of <100 nM. RORγt modulator 5 has the potential for inflammatory, metabolic, autoimmune and other diseases mediated by RORγ study (WO2017132432A1; compound 2).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RORγt/DHODH-IN-1

Cat. No.: HY-142843

RORγt/DHODH-IN-1 (compound (R)-14d) is a potent and orally active dual **RORγt/DHODH** inhibitor, with **IC_{50}**s of 0.083 μM and 0.172 μM, respectively. RORγt/DHODH-IN-1 exhibits remarkable in vivo anti-inflammatory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RORγt/DHODH-IN-2

Cat. No.: HY-142834

RORγt/DHODH-IN-2 (compound 1) is a potent dual **RORγt/DHODH** inhibitor. RORγt/DHODH-IN-2 can be used for inflammatory bowel disease (IBD) research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RORγt/DHODH-IN-3

Cat. No.: HY-142847

RORγt/DHODH-IN-3 (compound (S)-14d) is a dual **RORγt/DHODH** inhibitor, with **IC_{50}**s of 0.098 μM and 0.432 μM, respectively. RORγt/DHODH-IN-3 exhibits remarkable in vivo anti-inflammatory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

S18-000003

Cat. No.: HY-119366

S18-000003 is a potent, selective and orally active inhibitor of **retinoic acid receptor-related orphan receptor-gamma-t (RORγt)**, with an IC_{50} of <30 nM towards human RORγt in competitive binding assays.



Purity: 99.26%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SHR168442

Cat. No.: HY-115879

SHR168442 is a modulator of retinoid-related orphan receptor gamma (RORγ) with an IC_{50} value of 0.035 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SR0987

Cat. No.: HY-101454

SR0987, a SR1078 analog, is a **RORγt** agonist, with an EC_{50} of 800 nM. SR0987 increases IL17 expression while repressing the expression of PD-1.



Purity: 99.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SR1001

Cat. No.: HY-13421

SR1001 is a selective ROR_{α} and $ROR_{\gamma t}$ inverse agonist with K_is 172 and 111 nM, respectively.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

SR1078

Cat. No.: HY-14422

SR1078 is a selective agonist of retinoic acid receptor-related orphan receptor α/γ (**RORα/RORγ**). SR1078 directly binds to the ligand binding domain of RORα and RORγ and increases the transcriptional activity of these receptors, leading to stimulation of RORα/γ target gene transcription.



Purity: 99.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SR2211

Cat. No.: HY-16998

SR2211 is a potent, selective synthetic **RORγ** modulator and functions as an inverse agonist, with a K_i of 105 nM and an IC_{50} of ~320 nM.



Purity: 98.59%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

SR3335

(ML 176)

Cat. No.: HY-14413

SR3335 (ML 176) is a selective **RORα** inverse agonist that directly binds to RORα with a K_i of 220 nM.



Purity: 99.43%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

T0901317

Cat. No.: HY-10626

T0901317 is an orally active and highly selective **LXR** agonist with an EC_{50} of 20 nM for LXRα. T0901317 activates **FXR** with an EC_{50} of 5 μM. T0901317 is **RORα** and **RORγ** dual inverse agonist with K_i values of 132 nM and 51 nM, respectively.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

TAK-828F

Cat. No.: HY-111509

TAK-828F is a potent, selective, and orally available retinoic acid receptor-related orphan receptor γt (**RORγt**) inverse agonist (binding IC_{50}=1.9 nM, reporter gene IC_{50}=6.1 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TMP778

Cat. No.: HY-102075A

TMP778 is a potent and selevtive **RORγt** inverse agonist, with an IC_{50} of 7 nM in FRET assay.



Purity: 99.41%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TMP780

Cat. No.: HY-102075B

TMP780 is an inverse agonist of **RORγt** with an IC_{50} of 13 nM. RORγt is a tractable drug target for the treatment of cutaneous inflammatory disorders.



Purity: 99.51%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TMP920

Cat. No.: HY-117819

TMP920 is a highly potent and selective **RORγt** antagonist. TMP920 inhibits RORγt binding to the SRC1 peptide with an IC_{50} of 0.03 μM.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Vimirogant

(VTP-43742)

Cat. No.: HY-103637

Vimirogant (VTP-43742) is a potent, selective, and orally active **RORγt** inhibitor (K_i=3.5 nM; IC_{50}=17 nM). Vimirogant exhibits >1000-fold selectivity versus the RORα and RORβ isotypes.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg

Vimirogant hydrochloride

(VTP-43742 hydrochloride)

Cat. No.: HY-103637A

Vimirogant (VTP-43742) hydrochloride is a potent, selective, and orally active **RORγt** inhibitor (K_i=3.5 nM; IC_{50}=17 nM). Vimirogant hydrochloride exhibits >1000-fold selectivity versus the RORα and RORβ isotypes.



Purity: 98.33%
Clinical Data: Phase 2
Size: 1 mg, 5 mg, 10 mg

XY018

Cat. No.: HY-120210

XY018 is a potent **ROR-γ**-selective antagonist. XY018 inhibits ROR-γ constitutive activity in 293T cells with high potency (EC_{50}, 190 nM). XY018 binds to the ROR-γ hydrophobic ligand binding domain (LBD).



Purity: 99.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

XY101

Cat. No.: HY-128604

XY101 is a potent, selective, metabolically stable and orally available **RORγ** inverse agonist with an IC_{50} of 30 nM and a K_d of 380 nM.



Purity: 98.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg